Last reviewed 2026-05-13 · How we verify

preservative free tafluprost 0.0015%

preservative free tafluprost 0.0015% is a Prostaglandin F analog Small molecule drug developed by Tun Hussein Onn National Eye Hospital. It is currently FDA-approved for Open-angle glaucoma, Ocular hypertension.

Tafluprost is a prostaglandin F analog that binds to prostaglandin F receptors in the eye to increase uveoscleral outflow of aqueous humor, thereby reducing intraocular pressure.

Tafluprost is a prostaglandin F analog that binds to prostaglandin F receptors in the eye to increase uveoscleral outflow of aqueous humor, thereby reducing intraocular pressure. Used for Open-angle glaucoma, Ocular hypertension.

At a glance

Mechanism of action

Tafluprost mimics the action of prostaglandin F by activating FP receptors on the ciliary muscle bundle and trabecular meshwork. This activation enhances drainage of aqueous humor through the unconventional (uveoscleral) pathway, leading to decreased intraocular pressure. The preservative-free formulation reduces ocular surface irritation compared to preserved versions.

Approved indications

• Open-angle glaucoma
• Ocular hypertension

Common side effects

• Conjunctival hyperemia
• Eye irritation/discomfort
• Increased iris pigmentation
• Eyelash growth (hypertrichosis)
• Periocular skin darkening

Key clinical trials

• A Study of DE-111A on the Treatment of Open Angle Glaucoma or Ocular Hypertension (PHASE3)
• Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting
• Tafluprost Preservative Free Switch Study (PHASE4)
• Preservative-Free Tafluprost (MK-2452) for the Treatment of Open-Angle Glaucoma or Ocular Hypertension (MK-2452-002) (PHASE3)
• A Study to Evaluate Pharmacokinetics of Tafluprost Ophthalmic Solution (0.0015%) in Pediatric Patients With Glaucoma or Ocular Hypertension (PHASE1)
• Preservative-Free MK2452 (Tafluprost) for Open-Angle Glaucoma/Ocular Hypertension (MK2452-001)(COMPLETED) (PHASE3)
• Efficacy and Tolerability of Preservative-free 0.0015% Tafluprost in Glaucoma Patients (PHASE4)
• The Effects of Preservative-free Prostaglandin Eye Drops in Sign and Symptoms on the Eyes of Patients With Glaucoma (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• preservative free tafluprost 0.0015% CI brief — competitive landscape report
• preservative free tafluprost 0.0015% updates RSS · CI watch RSS
• Tun Hussein Onn National Eye Hospital portfolio CI

Frequently asked questions about preservative free tafluprost 0.0015%

Related

• Drug class: All Prostaglandin F analog drugs
• Target: All drugs targeting Prostaglandin F receptor (FP receptor)
• Manufacturer: Tun Hussein Onn National Eye Hospital — full pipeline
• Therapeutic area: All drugs in Ophthalmology
• Indication: Drugs for Open-angle glaucoma
• Indication: Drugs for Ocular hypertension
• Compare: preservative free tafluprost 0.0015% vs similar drugs
• Pricing: preservative free tafluprost 0.0015% cost, discount & access